At this year’s German Biotechnology Days (DBT), held in Leipzig on April 21 and 22, the LPI networked with the national biotechnology community. The DBT brings together entrepreneurs, scientists, political partners, investors, funding agencies, and government authorities every year.
At the booth of Innovativ Thüringen, the LPI presented itself alongside the InfectoGnostics Research Campus and the Leibniz Health Technologies. As a translational center, the LPI offers support for bringing clinically relevant innovations to market, thereby bridging the gap between technology development and real-world application.
In addition to catching up with familiar faces, the DBT provided an ideal opportunity to establish numerous new contacts for collaborations and future partnerships. The First-in-Patient Unit (FiPU) has generated particular interest – pilot projects for clinical validation can begin as early as next year in this area of the Intensive Care Units.
The session titled “Antibiotic Resistance: Fighting the Silent Pandemic” offered fascinating insights, highlighting and discussing diagnostic and therapeutic advances in the fight against antimicrobial resistance.
The event demonstrate that there is no shortage of innovation in Germany. Rather, the focus must be clearly placed on the structured translation of research into marketable applications. This is where the LPI infrastructure comes in: It will support the systematic translation of scientific excellence into clinically validated, regulatory-ready, and industrially scalable solutions.
We look forward to meeting again at the next German Biotech Days in 2027!
Pictures: LPIgGmbH / Sarah Krautwurst // German Biotech Days, Leipzig, April 21-22, 2026
